M A Jacobson

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California, San Francisco and The Medical Service, San Francisco General Hospital, San Francisco, CA, USA
    AIDS 16:1147-54. 2002
  2. ncbi request reprint Results of a cytomegalovirus (CMV)-specific CD8+/interferon- gamma+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis
    Mark A Jacobson
    Positive Health Program, Department of Medicine, and San Francisco General Hospital General Clinical Research Center, University of California San Francisco, San Francisco, California, USA
    J Infect Dis 189:1362-73. 2004
  3. pmc Poor predictive value of cytomegalovirus (CMV)-specific T cell assays for the development of CMV retinitis in patients with AIDS
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California San Francisco, CA, USA
    Clin Infect Dis 46:458-66. 2008
  4. ncbi request reprint Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/microL
    M A Jacobson
    Positive Health Program, Department of Medicine, University of California, San Francisco, CA 94110, USA
    J Infect Dis 182:1070-6. 2000
  5. pmc Do CD4+ T cell functional responses to Epstein-Barr virus provide protective immunity against CNS lymphoma in AIDS?
    Mark A Jacobson
    Positive Health Program, University of California San Francisco, San Francisco General Hospital, San Francisco, California, United States of America
    PLoS Med 4:e110. 2007
  6. ncbi request reprint Cytomegalovirus (CMV)-specific CD4+ T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy
    M A Jacobson
    University of California San Francisco, Department of Medicine, Ward 84, 995 Potrero St, San Francisco, CA 94110, USA
    J Infect Dis 183:1399-404. 2001
  7. ncbi request reprint Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California San Francisco, and San Francisco General Hospital General Clinical Research Center, CA 94110, United States
    Vaccine 24:5311-9. 2006
  8. ncbi request reprint Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California San Francisco, 4th Floor, 995 Potrero, San Francisco, CA 94110, USA
    J Clin Virol 35:332-7. 2006
  9. ncbi request reprint Effect of long-term highly active antiretroviral therapy in restoring HIV-induced abnormal B-lymphocyte function
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California San Francisco, 995 Potrero, San Francisco, CA 94110, USA
    J Acquir Immune Defic Syndr 31:472-7. 2002
  10. ncbi request reprint Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California San Francisco 94110, USA
    HIV Clin Trials 6:246-53. 2005

Collaborators

Detail Information

Publications43

  1. ncbi request reprint A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California, San Francisco and The Medical Service, San Francisco General Hospital, San Francisco, CA, USA
    AIDS 16:1147-54. 2002
    ..The primary objective of this study was to determine the safety and immunologic activity of repeated recombinant human IL-12 (rhIL-12) dosing in HIV-infected patients over a broad range of the HIV disease spectrum...
  2. ncbi request reprint Results of a cytomegalovirus (CMV)-specific CD8+/interferon- gamma+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis
    Mark A Jacobson
    Positive Health Program, Department of Medicine, and San Francisco General Hospital General Clinical Research Center, University of California San Francisco, San Francisco, California, USA
    J Infect Dis 189:1362-73. 2004
    ..These data suggest that further testing of the CMV-specific CD8+/IFN- gamma+ CFC assay, for clinical utility in predicting incident and progressive CMVR disease, is warranted...
  3. pmc Poor predictive value of cytomegalovirus (CMV)-specific T cell assays for the development of CMV retinitis in patients with AIDS
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California San Francisco, CA, USA
    Clin Infect Dis 46:458-66. 2008
    ..We examined the potential clinical utility of using a cytomegalovirus (CMV)-specific T cell immunoassay to determine the risk of developing new-onset CMV retinitis (CMVR) in patients with acquired immunodeficiency syndrome (AIDS)...
  4. ncbi request reprint Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/microL
    M A Jacobson
    Positive Health Program, Department of Medicine, University of California, San Francisco, CA 94110, USA
    J Infect Dis 182:1070-6. 2000
    ..Single rhIL-12 doses of 30-300 ng/kg were well tolerated and had biologic activity that could potentially be of benefit in the treatment of HIV disease or its complications...
  5. pmc Do CD4+ T cell functional responses to Epstein-Barr virus provide protective immunity against CNS lymphoma in AIDS?
    Mark A Jacobson
    Positive Health Program, University of California San Francisco, San Francisco General Hospital, San Francisco, California, United States of America
    PLoS Med 4:e110. 2007
  6. ncbi request reprint Cytomegalovirus (CMV)-specific CD4+ T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy
    M A Jacobson
    University of California San Francisco, Department of Medicine, Ward 84, 995 Potrero St, San Francisco, CA 94110, USA
    J Infect Dis 183:1399-404. 2001
    ..However, 6 of these 10 subjects also had negative CMV-specific immune responses > or =1 time. Such patients may be at risk for future CMV disease progression and should be closely monitored...
  7. ncbi request reprint Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California San Francisco, and San Francisco General Hospital General Clinical Research Center, CA 94110, United States
    Vaccine 24:5311-9. 2006
    ..5-2.0 microg rhIL-12 compared to lower dose or no rhIL-12. Thus, adjuvant IL-12 may be a promising strategy for improving antibody and T cell immune responses to a CMV vaccine...
  8. ncbi request reprint Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California San Francisco, 4th Floor, 995 Potrero, San Francisco, CA 94110, USA
    J Clin Virol 35:332-7. 2006
    ..Towne cytomegalovirus (CMV) vaccine is safe and immunogenic, though its protective efficacy has yet to be optimized...
  9. ncbi request reprint Effect of long-term highly active antiretroviral therapy in restoring HIV-induced abnormal B-lymphocyte function
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California San Francisco, 995 Potrero, San Francisco, CA 94110, USA
    J Acquir Immune Defic Syndr 31:472-7. 2002
    ..This study provides the longest reported observation to date of the effect of HAART on HIV-induced abnormal antibody-mediated immunity. Larger and longer-term studies of HAART effect on B-cell reconstitution are needed...
  10. ncbi request reprint Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California San Francisco 94110, USA
    HIV Clin Trials 6:246-53. 2005
    ..However, the pharmacokinetics of clarithromycin ER in AIDS patients with or at risk for dMAC has not been previously investigated...
  11. doi request reprint A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain)
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California San Francisco, 4th Floor, 995 Potrero, San Francisco, CA 94110, United States
    Vaccine 27:1540-8. 2009
    ..02 and 0.03, respectively). Furthermore, there was a trend toward more DNA-vaccinated subjects than controls developing a gB-specific IFN-gamma T-cell response after Towne administration (47% vs. 0%, p=0.06)...
  12. pmc Human herpesvirus replication and abnormal CD8+ T cell activation and low CD4+ T cell counts in antiretroviral-suppressed HIV-infected patients
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California San Francisco and The Medical Service, San Francisco General Hospital, San Francisco, CA, USA
    PLoS ONE 4:e5277. 2009
    ....
  13. ncbi request reprint Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine
    M A Jacobson
    Department of Medicine, University of California, San Francisco
    J Infect Dis 159:1029-36. 1989
    ..05). Serum beta 2-microglobulin appears to be a sensitive marker for in vivo antiretroviral drug activity and may be a better marker than serum p24 antigen for early intervention trials involving antiretroviral agents...
  14. ncbi request reprint Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon- gamma and interleukin-2 and have a CD8+ cell early maturational phenotype
    Elizabeth Sinclair
    Division of Experimental Medicine, University of California, San Francisco, CA, USA
    J Infect Dis 194:1537-46. 2006
    ..Recovery from AIDS-related CMVR after the initiation of antiretroviral therapy may be mediated by CMV-specific CD4(+) and CD8(+) T cells capable of promoting antigen-specific CD8(+) T cell proliferation...
  15. ncbi request reprint Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy
    M A Jacobson
    Department of Medicine, University of California, San Francisco 94110, USA
    Lancet 349:1443-5. 1997
    ..In previous natural history studies and clinical trials, AIDS-related cytomegalovirus (CMV) retinitis has occurred primarily in patients with absolute CD4 counts of 50 cells/microL or less (0.05 x 10(9)/L) at the time of diagnosis...
  16. ncbi request reprint Eradication of AIDS-related disseminated mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy
    J A Aberg
    Department of Medicine, University of California, San Francisco, USA
    J Infect Dis 178:1446-9. 1998
    ..It appears that disseminated MAC infection can be cured by prolonged antimycobacterial therapy in some persons who experience sustained CD4 lymphocyte increases while receiving HAART...
  17. ncbi request reprint The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine
    M A Jacobson
    Department of Medicine, University of California, San Francisco General Hospital 94110, USA
    AIDS 9:727-34. 1995
    ..This information may be useful to clinicians and patients who are making decisions about initiating or changing antiretroviral therapy...
  18. pmc CMV antigen-specific CD4+ and CD8+ T cell IFNgamma expression and proliferation responses in healthy CMV-seropositive individuals
    Elizabeth Sinclair
    San Francisco General Hospital General Clinical Research Center, University of California San Francisco, California, USA
    Viral Immunol 17:445-54. 2004
    ..These findings support the concept that a multiplicity of antigen-specific functional immune responses and persistence of robust virus-specific CD4+T cells are important components of protective immunity in this chronic viral infection...
  19. pmc Loss of T cell responses following long-term cryopreservation
    Rachel E Owen
    Blood Systems Research Institute, 270 Masonic Avenue, San Francisco, CA 94118, USA
    J Immunol Methods 326:93-115. 2007
    ..Long-term cryopreservation, however, may lead to the loss of CD4(+) T cell responses and mild skewing of T cell phenotypic marker expression...
  20. pmc Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine
    M A Jacobson
    Department of Medicine, University of California, San Francisco
    BMJ 302:73-8. 1991
    ....
  21. ncbi request reprint Red cell transfusion therapy for anemia in patients with AIDS and ARC: incidence, associated factors, and outcome
    M A Jacobson
    Department of Medicine, University of California, San Francisco
    Transfusion 30:133-7. 1990
    ..2 for transfusion-requiring anemia. In 80 percent of cases, the patient returned home after transfusion. Most PRBC transfusions administered to AIDS or ARC patients were optimal therapy...
  22. ncbi request reprint Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection
    Jeffrey M Jacobson
    Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, New York, New York 10003, USA
    J Infect Dis 188:1804-14. 2003
    ..Studies have reported that plasma human immunodeficiency virus type 1 (HIV-1) RNA levels and CD4+ lymphocyte counts in HIV-infected patients improved after treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF)...
  23. ncbi request reprint A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study G
    J E Feinberg
    Department of Medicine, University of Cincinnati, Ohio 45267 0405, USA
    J Infect Dis 177:48-56. 1998
    ..06). Toxicity and earlier medication discontinuation were more common in this group. Valaciclovir significantly reduces the risk of CMV disease. Further exploration of a better-tolerated dose is warranted...
  24. ncbi request reprint Mycobacterial diseases. Tuberculosis and Mycobacterium avium complex
    M A Jacobson
    Department of Medicine, University of California, San Francisco
    Infect Dis Clin North Am 2:465-74. 1988
    ..The relationship between MAC infection and constitutional symptoms as well as the value of antimycobacterial therapy for disseminated MAC is controversial...
  25. ncbi request reprint Presence of macrolide resistance in respiratory flora of HIV-Infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis
    J A Aberg
    Department of Medicine, University of California, San Francisco, USA
    HIV Clin Trials 2:453-9. 2001
    ....
  26. ncbi request reprint Phase I study of combination therapy with intravenous cidofovir and oral ganciclovir for cytomegalovirus retinitis in patients with AIDS
    M A Jacobson
    Department of Medicine AIDS Program, University of California at San Francisco, USA
    Clin Infect Dis 28:528-33. 1999
    ..Less frequent administration of cidofovir in combination with oral ganciclovir should be prospectively studied to determine if the incidence of treatment-associated toxicity might be reduced...
  27. ncbi request reprint Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations
    F T Aweeka
    Department of Clinical Pharmacy, University of California, San Francisco 94143 0622, USA
    J Acquir Immune Defic Syndr Hum Retrovirol 20:350-7. 1999
    ..To develop specific dosage guidelines, information on the disposition of this compound in patients with varying degrees of renal function and those requiring dialysis is essential...
  28. ncbi request reprint Abundant expression of granzyme A, but not perforin, in granules of CD8+ T cells in GALT: implications for immune control of HIV-1 infection
    Barbara L Shacklett
    Gladstone Institute of Virology and Immunology GIVI, Department of Medicine, University of California San Francisco, San Francisco, CA 94141, USA
    J Immunol 173:641-8. 2004
    ..Furthermore, the relative absence of armed effector cells may serve to protect the integrity of rectal mucosa under normal conditions, but might also provide an early advantage to HIV-1 and other sexually transmitted viruses...
  29. pmc Development of cytomegalovirus (CMV) immune recovery uveitis is associated with Th17 cell depletion and poor systemic CMV-specific T cell responses
    DENNIS J HARTIGAN-O'CONNOR
    Division of Experimental Medicine, University of California, San Francisco, CA 94110, USA
    Clin Infect Dis 52:409-17. 2011
    ..Although the pathologic immune responses occur in the eye, immune dysregulation that allows for development of pathologic responses is presumably caused by faulty systemic immune cell reconstitution...
  30. pmc Trafficking of human immunodeficiency virus type 1-specific CD8+ T cells to gut-associated lymphoid tissue during chronic infection
    Barbara L Shacklett
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, California 94141 9100, USA
    J Virol 77:5621-31. 2003
    ..These studies demonstrate the feasibility of using tetramers to assess HIV-specific T cells in GALT and reveal that GALT is the site of an active CD8(+) T-cell response during chronic infection...
  31. ncbi request reprint Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex
    M A Jacobson
    Department of Medicine, University of California, San Francisco
    Am J Med 85:172-6. 1988
    ..aureus bacteremia, with a higher late metastatic complication rate than that reported for recent historical control subjects...
  32. ncbi request reprint Zidovudine-induced fever
    M A Jacobson
    Department of Medicine, University of California San Francisco
    J Acquir Immune Defic Syndr 2:382-8. 1989
    ..Zidovudine may cause fever as a severe adverse effect in patients with AIDS. Either type III or type IV hypersensitivity may mediate this reaction...
  33. ncbi request reprint Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California, San Francisco, USA
    AIDS 17:917-9. 2003
  34. pmc Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding
    Jacob P Lalezari
    Quest Clinical Research, San Francisco, California, USA
    Antimicrob Agents Chemother 46:2969-76. 2002
    ..9 to 3.7 log(10) PFU/ml among the four regimens evaluated for anti-HCMV activity. 1263W94 was generally well tolerated; taste disturbance was the most frequently reported adverse event over the 28-day dosing period...
  35. ncbi request reprint Effect of a four-week course of interleukin-10 on cytokine production in a placebo-controlled study of HIV-1-infected subjects
    Gregory B Pott
    Department of Medicine, Division of Infectious Diseases, University of Colorado at Denver and Health Sciences Center, 4200 E 9th Ave Box B168, Denver, CO 80262, USA
    Eur Cytokine Netw 18:49-58. 2007
    ....
  36. pmc Invasive fungal sinusitis and meningitis due to Arthrographis kalrae in a patient with AIDS
    P V Chin-Hong
    Department of Medicine, University of California, San Francisco, and the Medical Service, San Francisco General Hospital, San Antonio, Texas, USA
    J Clin Microbiol 39:804-7. 2001
    ..There was also an associated fungal meningitis and vasculitis with fungal thrombosis and multiple recent infarcts that involved the frontal lobes, right caudate nucleus, and putamen. Post mortem cultures were positive for A. kalrae...
  37. ncbi request reprint Cytomegalovirus (CMV) polymerase chain reaction profiles in individuals with advanced human immunodeficiency virus infection: relationship to CMV disease
    Mostafa A Nokta
    Department of Internal Medicine, Division of Infectious Disease, University of Texas Medical Branch, Galveston, TX 77555 0835, USA
    J Infect Dis 185:1717-22. 2002
    ..42; 95% CI, 2.87-6.81). Change in cumulative PCR status was informative for the risk of subsequent CMV disease...
  38. ncbi request reprint Association of cytomegalovirus (CMV)-specific CD4+ T lymphocyte reactivity and protective immunity against acquired immunodeficiency syndrome-related CMV retinitis
    Mark A Jacobson
    J Infect Dis 186:1701-2; author reply 1702-3. 2002
  39. ncbi request reprint Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy
    Douglas A Jabs
    Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ophthalmology 112:771-9. 2005
    ..To evaluate risk factors for mortality among patients with AIDS in the era of highly active antiretroviral therapy (HAART), particularly the effect of cytomegalovirus (CMV)...
  40. ncbi request reprint Editorial comment: failure of HAART to reconstitute CMV-specific protective immunity
    Mark A Jacobson
    AIDS Read 15:188. 2005
  41. ncbi request reprint Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067
    Ronald D'Amico
    Beth Israel Medical Center, New York, New York 10003, USA
    J Clin Immunol 25:106-15. 2005
    ..Although initiation of potent antiretroviral therapy (ART) has significantly improved immune perturbations in individuals with AIDS, it is unclear which factors are most important in determining the degree of immune reconstitution...
  42. ncbi request reprint Avidity of antibodies to cytomegalovirus in HIV-seropositive patients with and without CMV retinitis
    Beth C Marshall
    Department of Pediatrics, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia, USA
    Viral Immunol 17:101-8. 2004
    ..These results indicate antibody avidity is unaltered in HIV disease and does not play an important role in the pathogenesis of AIDS-related CMV disease...
  43. doi request reprint Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic
    Christopher J Graber
    J Acquir Immune Defic Syndr 49:231-3. 2008

Research Grants9

  1. Adjunct rhIL-12 enhance THI response to viral vaccine?
    Mark Jacobson; Fiscal Year: 2004
    ..g. CMV, HSV and HIV). ..
  2. CMV Immune Response & Long-Term Outcome of CMV Retinitis
    Mark Jacobson; Fiscal Year: 2005
    ....
  3. HIV Epitope Specific T Cell Responses and Control of HIV Replication
    Mark Jacobson; Fiscal Year: 2007
    ....
  4. Aberrant T Cell Function and Immunopathogenesis of CMV Immune Recovery Uveitis
    Mark Jacobson; Fiscal Year: 2007
    ..There is no effective therapy for CMV IRU. Thus, understanding the disease mechanism of CMV IRU could facilitate development of effective therapy for CMV IRU or diagnostic or treatment strategies to prevent CMV IRU. ..